Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
5174- Ash,    Withaferin A is a potent inhibitor of angiogenesis
- in-vitro, Nor, HUVECs
Inflam↓, *TumCP↓, cycD1/CCND1↓, NF-kB↓, angioG↓,
5175- Ash,    Withaferin A Induces Proteasome Inhibition, Endoplasmic Reticulum Stress, the Heat Shock Response and Acquisition of Thermotolerance
- in-vitro, Cerv, CCL-102
Inflam↓, AntiTum↑, Proteasome↓, ER Stress↑, HSPs↑, GRP94↑, Akt↑, eff↑, HSP70/HSPA5↑,
4660- Ash,    Withaferin A Alone and in Combination with Cisplatin Suppresses Growth and Metastasis of Ovarian Cancer by Targeting Putative Cancer Stem Cells
- in-vitro, Ovarian, NA
CSCs↓, TumCG↓, TumMeta↓, CD44↓, CD34↓, OCT4↓, NOTCH1↓, HEY1↓,
4677- Ash,    Withaferin A (WFA) inhibits tumor growth and metastasis by targeting ovarian cancer stem cells
- vitro+vivo, Ovarian, NA
CSCs↓, Securin↓, ALDH1A1↓,
4678- Ash,    Identification of Withaferin A as a Potential Candidate for Anti-Cancer Therapy in Non-Small Cell Lung Cancer
- vitro+vivo, NSCLC, H1975
ROS↑, AntiTum↑, CSCs↓, mTOR↓, STAT3↓, ChemoSen↑, Keap1↑, NRF2↓,
4679- Ash,    Induced cancer stem-like cells as a model for biological screening and discovery of agents targeting phenotypic traits of cancer stem cell
- in-vitro, NA, NA
CSCs↓,
5384- AsP,  MEL,    Synergistic Anticancer Effect of Melatonin and Ascorbyl Palmitate Nanoformulation: A Promising Combination for Cancer Therapy
- in-vivo, Var, NA
AntiCan↑, TumCG↓, Apoptosis↑, DNAdam↑, TumCCA↑, IL6↓, STAT3↓, TumCP↓, Ki-67↓, TumCI↓, TumMeta↓, MMP9↓, eff↑, *Catalase↑, *SOD↑, *GSH↑, *MDA↓, *NO↓, *antiOx↑, *hepatoP↑, *RenoP↑,
5385- AsP,  GoldNP,  GEM,    Development of ascorbyl palmitate based hydrophobic gold nanoparticles as a nanocarrier system for gemcitabine delivery
- in-vitro, BC, NA
ROS↑, Fenton↑, BioAv↑, EPR↑,
5388- AsP,    Capacity of Ascorbyl Palmitate to Produce the Ascorbyl Radical in Vitro: an Electron Spin Resonance Investigation
- in-vitro, Nor, NA
other↑,
5389- AsP,  Tras,    ASCORBYL PALMITATE ENHANCES ANTI-PROLIFERATIVE EFFECT OF TRASTUZUMAB IN HER2-POSITIVE BREAST CANCER CELLS
tumCV↓, eff↑, P53↑, BAX↑, Casp3↑, Casp8↑, Bcl-2↓, Apoptosis↑, p‑p38↓, ERK↓, PI3K↓,
5391- AsP,    Research Progress of Ascorbyl Palmitate in Drug Delivery and Cancer Therapy
- Review, Var, NA
*antiOx↑, toxicity↓,
5387- AsP,  PacT,    Ascorbyl palmitate-incorporated paclitaxel-loaded composite nanoparticles for synergistic anti-tumoral therapy
- in-vivo, Melanoma, B16-F10
Dose↝, TumCG↓, TumCP↓, BioAv↓, BioAv↑, other↑, Apoptosis↑, Bax:Bcl2↑, EPR↑, toxicity↝,
1146- AsP,    Potential use of nanoformulated ascorbyl palmitate as a promising anticancer agent: First comparative assessment between nano and free forms
- in-vivo, Nor, NA
TumCCA↑, Apoptosis↑, IL6↓, STAT3↓, angioG↓, TumMeta↓, VEGF↓, MMP9↓, SOD↑, Catalase↑, GSH↓, MDA↓, NO↓, *BioAv↑,
4814- ASTX,    Chemopreventive and therapeutic efficacy of astaxanthin against cancer: A comprehensive review
- Review, Var, NA
Apoptosis↑, EMT↓, AntiCan↑, *cardioP↑, *neuroP↑, TumCG↓, *antiOx↑, *Bacteria↓, *Imm↑, *hepatoP↑, *AntiDiabetic↑, ROS↓, *chemoPv↑,
4825- ASTX,    In vivo protective efficacy of astaxanthin against ionizing radiation-induced DNA damage
- in-vivo, Nor, NA
*DNAdam↓, *radioP↑,
4824- ASTX,  Rad,    Astaxanthin protects the radiation-induced lung injury in C57BL/6 female mice
- in-vivo, Nor, NA
*radioP↑, Inflam↓,
4823- ASTX,    Astaxanthin increases radiosensitivity in esophageal squamous cell carcinoma through inducing apoptosis and G2/M arrest
- in-vitro, ESCC, NA
RadioS↑, Apoptosis↑, TumCCA↑, Bcl-2↓, CycB/CCNB1↓, CDC2↓, BAX↑,
4822- ASTX,  Rad,    Astaxanthin Synergizes with Ionizing Radiation (IR) in Oral Squamous Cell Carcinoma (OSCC)
tumCV↓, selectivity↑, RadioS↑, GPx4↓, Ferroptosis↑,
4821- ASTX,    Astaxanthin Reduces Stemness Markers in BT20 and T47D Breast Cancer Stem Cells by Inhibiting Expression of Pontin and Mutant p53
- in-vitro, BC, SkBr3 - in-vitro, BC, BT20 - in-vitro, BC, T47D
Apoptosis↑, CSCs↓, OCT4↓, Nanog↓, TumCP↓,
4820- ASTX,    Astaxanthin suppresses the malignant behaviors of nasopharyngeal carcinoma cells by blocking PI3K/AKT and NF-κB pathways via miR-29a-3p
- in-vitro, NPC, NA
TumCP↓, TumCI↓, Apoptosis↑, TumCCA↑, cycD1/CCND1↓, Bcl-2↓, P21↑, BAX↑, PI3K↓, Akt↓, NF-kB↓, miR-29b↑,
4819- ASTX,    Astaxanthin Induces Apoptosis in MCF-7 Cells through a p53-Dependent Pathway
- in-vitro, BC, MCF-7
antiOx↑, AntiTum↑, TumCD↑, P53↑, P21↑, Apoptosis↑, Dose↝, Casp3↑,
4818- ASTX,  MEL,    Effect of astaxanthin and melatonin on cell viability and DNA damage in human breast cancer cell lines
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, T47D - in-vitro, Nor, MCF10
TumCD↑, DNAdam↑, *antiOx↑, *AntiTum↑, Inflam↓, tumCV↓, Bcl-2↓, Apoptosis↓, selectivity↑, eff↑, Dose↓,
4817- ASTX,    Low Dose Astaxanthin Treatments Trigger the Hormesis of Human Astroglioma Cells by Up-Regulating the Cyclin-Dependent Kinase and Down-Regulated the Tumor Suppressor Protein P53
- in-vitro, GBM, U251
Dose⇅, ROS∅, SOD↑, CDK1↑, P53↓, TumCP⇅, ROS↑,
4816- ASTX,    Potent carotenoid astaxanthin expands the anti-cancer activity of cisplatin in human prostate cancer cells
- in-vitro, Pca, NA
*antiOx↑, *Inflam↓, ChemoSen↑, E-cadherin↑, N-cadherin↓, VEGF↓, cMyc↓, PSA↓, cl‑Casp3↑, PARP1↑,
4815- ASTX,    The Promising Effects of Astaxanthin on Lung Diseases
- Review, Var, NA
Dose↑, *BioAv↝, *BioAv↝, *antiOx↑, *NRF2↑, *ERK↓,
4804- ASTX,    Astaxanthin in cancer therapy and prevention (Review)
- Review, Var, NA - Review, AD, NA
*antiOx↑, *Inflam↓, ChemoSen⇅, chemoP↑, BioAv↑, TumCP↑, ROS⇅, Apoptosis↑, PI3K↑, Akt↑, GSK‐3β↑, NRF2↑, AntiCan↑, *neuroP↑, eff↑, AntiTum↑,
4813- ASTX,    Astaxanthin Prevents Oxidative Damage and Cell Apoptosis Under Oxidative Stress Involving the Restoration of Mitochondrial Function
- in-vitro, AD, NA
*antiOx↑, *Apoptosis↓, *AntiTum↑, *ROS↓, *MMP↑, *neuroP↑,
4812- ASTX,    Astaxanthin suppresses the metastasis of colon cancer by inhibiting the MYC-mediated downregulation of microRNA-29a-3p and microRNA-200a
- in-vitro, CRC, HCT116
miR-29b↑, miR-200b↑, MMP2↓, Zeb1↓, EMT↓, Apoptosis↑, ERK↓, MAPK↓, PI3K↓, Akt↓, MMPs↓, TumMeta↓,
4811- ASTX,    Astaxanthin reduces MMP expressions, suppresses cancer cell migrations, and triggers apoptotic caspases of in vitro and in vivo models in melanoma
- vitro+vivo, Melanoma, A375 - vitro+vivo, Melanoma, A2058
ROS↓, MMPs↓, TumCMig↓, TumMeta↓, TumCCA↑, antiOx↑, MMP1↓, MMP2↓, MMP9↓,
4810- ASTX,    Effects of Astaxanthin on the Proliferation and Migration of Breast Cancer Cells In Vitro
- in-vitro, BC, MDA-MB-231 - in-vitro, Nor, MCF10
TumCP↓, TumCMig↓, selectivity↑, *BDNF↑, *ROS↓, *TNF-α↓, *IL6↓, *IFN-γ↓, *NF-kB↓, BAX⇅, Bcl-2↓, *antiOx↑, radioP↑, ChemoSen↑,
4809- ASTX,    Astaxanthin Inhibits Proliferation of Human Gastric Cancer Cell Lines by Interrupting Cell Cycle Progression
- in-vitro, GC, AGS - in-vitro, GC, MKN45
tumCV↓, TumCP↓, TumCCA↑, p‑ERK↓, p27↑, cycD1/CCND1↓, CDK4↓,
4808- ASTX,    Anti-Tumor Effects of Astaxanthin by Inhibition of the Expression of STAT3 in Prostate Cancer
- in-vitro, Pca, DU145 - in-vivo, NA, NA
TumCP↓, STAT3↓, Apoptosis↑, TumCMig↓, TumCI↓,
4807- ASTX,    An overview of the anticancer activity of astaxanthin and the associated cellular and molecular mechanisms
- Review, Var, NA
*antiOx↑, *neuroP↑, AntiCan↑, TumCG↓, TumCD↑, TumCMig↓, ChemoSen↑, chemoP↑, *BioAv↓, TumCP↓, TumCCA↑, Apoptosis↑, BioAv↑,
4806- ASTX,    Astaxanthin's Impact on Colorectal Cancer: Examining Apoptosis, Antioxidant Enzymes, and Gene Expression
- in-vitro, CRC, HCT116
BAX↑, Casp3↑, Apoptosis↑, Bcl-2↓, MDA↓, ROS↓, SOD↑, Catalase↑, GPx↑, antiOx↑, TumCG↓, TumCP↓,
4805- ASTX,    Astaxanthin promotes apoptosis by suppressing growth signaling pathways in HT-29 colorectal cancer cells
- in-vitro, Colon, HT29
TumCP↓, Casp3↑, EGFR↓, HER2/EBBR2↓, ERK↓, Apoptosis↑,
5426- ASTX,  Cisplatin,    Astaxanthin Prevents a Decrease of Hemopoietic Activity in Head and Neck Cancer Patients Receiving Cisplatin Chemotherapy (Randomized Controlled Trial)
- Trial, HNSCC, NA
ROS↓, SOD↑, MDA↓, eff↑,
5427- ASTX,    Astaxanthin and Cancer Chemoprevention
- Review, Var, NA
chemoP↑, AntiCan↑, chemoPv↑, Risk↓, lipid-P↓, Pain↓, BioAv↑, Dose↝,
5417- ASTX,    Comparative Pharmacokinetic Study of Standard Astaxanthin and its Micellar Formulation in Healthy Male Volunteers
- Study, Nor, NA
*antiOx↑, *BioAv↓, *Dose↝, *BioAv↑,
5418- ASTX,    Astaxanthin supplementation mildly reduced oxidative stress and inflammation biomarkers: a systematic review and meta-analysis of randomized controlled trials
- Review, Nor, NA
*MDA↓, *SOD↑, *IL6↓, *ROS↓, *Inflam↓,
5419- ASTX,    Astaxanthin and other Nutrients from Haematococcus pluvialis—Multifunctional Applications
- Review, Nor, NA
*antiOx↑, *Inflam↓, *AntiDiabetic↓, AntiCan↑, *lipid-P↓, TumCP↓, Apoptosis↑, TumCCA↑, *SOD↑, *PGE2↓, *NO↓, *IL8↓, *IFN-γ↓, *cardioP↑, *NF-kB↓, *TNF-α↓, *BioAv↑,
5420- ASTX,    A New Tailored Nanodroplet Carrier of Astaxanthin Can Improve Its Pharmacokinetic Profile and Antioxidant and Anti-Inflammatory Efficacies
- in-vivo, Nor, NA
*eff↑, *SOD↑, *BioAv↑,
5421- ASTX,    Astaxanthin Inhibits PC-3 Xenograft Prostate Tumor Growth in Nude Mice
- in-vivo, Pca, NA
TumCG↑, Ki-67↑, PCNA↓, GutMicro↑, *Inflam↓, *cardioP↑, *ROS↓,
5422- ASTX,    Improved intestinal absorption and oral bioavailability of astaxanthin using poly (ethylene glycol)-graft-chitosan nanoparticles: preparation, in vitro evaluation, and pharmacokinetics in rats
- in-vivo, Nor, NA
*antiOx↑, *AntiDiabetic↑, *toxicity∅, *BioAv↓, *BioAv↑,
5423- ASTX,    Pharmacokinetic Profile of Astaxanthin Nanoemulsion Using HPLC (High-Performance Liquid Chromatography) With Oral Routes
- in-vivo, Nor, NA
*BioAv↓, *antiOx↑, *BioAv↑, *Half-Life↝,
5424- ASTX,    Astaxanthin exerts an adjunctive anti-cancer effect through the modulation of gut microbiota and mucosal immunity
- in-vivo, Nor, NA
*GutMicro↑, AntiCan↑, eff↑, AntiTum↑, ChemoSen↑,
5425- ASTX,    Multiple roles of fucoxanthin and astaxanthin against Alzheimer's disease: Their pharmacological potential and therapeutic insights
- in-vivo, AD, NA
*neuroP↑, *antiOx↑, *Inflam↑, *AChE↓, *BACE↓, *MAOA↓, *Aβ↓, *memory↑, *MDA↓, *SOD↑, *NRF2↑, *HO-1↑, *NF-kB↓, *GSK‐3β↓, *ChAT↑, *iNOS↓, *ROS↓, *BBB↑,
147- ATG,  EGCG,  CUR,    Increased chemopreventive effect by combining arctigenin, green tea polyphenol and curcumin in prostate and breast cancer cells
- in-vitro, Pca, LNCaP - in-vitro, Pca, MCF-7
Bax:Bcl2↑, NF-kB↓, PI3K/Akt↓, STAT3↓, chemoPv↑, TumCP↓, TumCCA↑, TumCMig↓,
5372- ATO,    Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
- Trial, APL, NA
Remission↑, OS↑, toxicity↓,
5373- ATO,    arsenic trioxide
- Human, APL, NA
Half-Life↝,
5375- ATO,    Improved Outcome with ATRA-Arsenic Trioxide Compared to ATRA-Chemotherapy in Non-High Risk Acute Promyelocytic Leukemia – Updated Results of the Italian-German APL0406 Trial on the Extended Final Series
- Trial, APL, NA
eff↑, OS↑,

Showing Research Papers: 951 to 1000 of 5772
Prev Page 20 of 116 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 5772

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 3,   Catalase↑, 2,   Fenton↑, 1,   Ferroptosis↑, 1,   GPx↑, 1,   GPx4↓, 1,   GSH↓, 1,   Keap1↑, 1,   lipid-P↓, 1,   MDA↓, 3,   NRF2↓, 1,   NRF2↑, 1,   ROS↓, 4,   ROS↑, 3,   ROS⇅, 1,   ROS∅, 1,   SOD↑, 4,  

Mitochondria & Bioenergetics ⓘ

CDC2↓, 1,  

Core Metabolism/Glycolysis ⓘ

cMyc↓, 1,   PI3K/Akt↓, 1,  

Cell Death ⓘ

Akt↓, 2,   Akt↑, 2,   Apoptosis↓, 1,   Apoptosis↑, 16,   BAX↑, 4,   BAX⇅, 1,   Bax:Bcl2↑, 2,   Bcl-2↓, 6,   Casp3↑, 4,   cl‑Casp3↑, 1,   Casp8↑, 1,   Ferroptosis↑, 1,   HEY1↓, 1,   MAPK↓, 1,   p27↑, 1,   p‑p38↓, 1,   Proteasome↓, 1,   TumCD↑, 3,  

Kinase & Signal Transduction ⓘ

HER2/EBBR2↓, 1,  

Transcription & Epigenetics ⓘ

other↑, 2,   tumCV↓, 4,  

Protein Folding & ER Stress ⓘ

ER Stress↑, 1,   GRP94↑, 1,   HSP70/HSPA5↑, 1,   HSPs↑, 1,  

DNA Damage & Repair ⓘ

DNAdam↑, 2,   P53↓, 1,   P53↑, 2,   PARP1↑, 1,   PCNA↓, 1,  

Cell Cycle & Senescence ⓘ

CDK1↑, 1,   CDK4↓, 1,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 3,   P21↑, 2,   Securin↓, 1,   TumCCA↑, 9,  

Proliferation, Differentiation & Cell State ⓘ

ALDH1A1↓, 1,   CD34↓, 1,   CD44↓, 1,   CSCs↓, 5,   EMT↓, 2,   ERK↓, 3,   p‑ERK↓, 1,   GSK‐3β↑, 1,   mTOR↓, 1,   Nanog↓, 1,   NOTCH1↓, 1,   OCT4↓, 2,   PI3K↓, 3,   PI3K↑, 1,   STAT3↓, 5,   TumCG↓, 6,   TumCG↑, 1,  

Migration ⓘ

E-cadherin↑, 1,   Ki-67↓, 1,   Ki-67↑, 1,   miR-200b↑, 1,   miR-29b↑, 2,   MMP1↓, 1,   MMP2↓, 2,   MMP9↓, 3,   MMPs↓, 2,   N-cadherin↓, 1,   TumCI↓, 3,   TumCMig↓, 5,   TumCP↓, 12,   TumCP↑, 1,   TumCP⇅, 1,   TumMeta↓, 5,   Zeb1↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 2,   EGFR↓, 1,   EPR↑, 2,   NO↓, 1,   VEGF↓, 2,  

Immune & Inflammatory Signaling ⓘ

IL6↓, 2,   Inflam↓, 4,   NF-kB↓, 3,   PSA↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,   BioAv↑, 5,   ChemoSen↑, 5,   ChemoSen⇅, 1,   Dose↓, 1,   Dose↑, 1,   Dose⇅, 1,   Dose↝, 3,   eff↑, 8,   Half-Life↝, 1,   RadioS↑, 2,   selectivity↑, 3,  

Clinical Biomarkers ⓘ

EGFR↓, 1,   GutMicro↑, 1,   HER2/EBBR2↓, 1,   IL6↓, 2,   Ki-67↓, 1,   Ki-67↑, 1,   PSA↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 7,   AntiTum↑, 5,   chemoP↑, 3,   chemoPv↑, 2,   OS↑, 2,   Pain↓, 1,   radioP↑, 1,   Remission↑, 1,   Risk↓, 1,   toxicity↓, 2,   toxicity↝, 1,  
Total Targets: 130

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 15,   Catalase↑, 1,   GSH↑, 1,   HO-1↑, 1,   lipid-P↓, 1,   MDA↓, 3,   NRF2↑, 2,   ROS↓, 5,   SOD↑, 5,  

Mitochondria & Bioenergetics ⓘ

MMP↑, 1,  

Cell Death ⓘ

Apoptosis↓, 1,   iNOS↓, 1,  

DNA Damage & Repair ⓘ

DNAdam↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

ERK↓, 1,   GSK‐3β↓, 1,  

Migration ⓘ

TumCP↓, 1,  

Angiogenesis & Vasculature ⓘ

NO↓, 2,  

Barriers & Transport ⓘ

BBB↑, 1,  

Immune & Inflammatory Signaling ⓘ

IFN-γ↓, 2,   IL6↓, 2,   IL8↓, 1,   Imm↑, 1,   Inflam↓, 5,   Inflam↑, 1,   NF-kB↓, 3,   PGE2↓, 1,   TNF-α↓, 2,  

Synaptic & Neurotransmission ⓘ

AChE↓, 1,   BDNF↑, 1,   ChAT↑, 1,   MAOA↓, 1,  

Protein Aggregation ⓘ

Aβ↓, 1,   BACE↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 4,   BioAv↑, 6,   BioAv↝, 2,   Dose↝, 1,   eff↑, 1,   Half-Life↝, 1,  

Clinical Biomarkers ⓘ

GutMicro↑, 1,   IL6↓, 2,  

Functional Outcomes ⓘ

AntiDiabetic↓, 1,   AntiDiabetic↑, 2,   AntiTum↑, 2,   cardioP↑, 3,   chemoPv↑, 1,   hepatoP↑, 2,   memory↑, 1,   neuroP↑, 5,   radioP↑, 2,   RenoP↑, 1,   toxicity∅, 1,  

Infection & Microbiome ⓘ

Bacteria↓, 1,  
Total Targets: 53

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page